HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SC002

structure in first source

Also Known As:

SC-002

Networked: 3 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        SC002: 3
- Sulfur Compounds: 278
  - Thiazines: 3
    - Cephalosporins: 4007
      - SC002: 3
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Cephalosporins: 4007
        SC002: 3

Experts

1.	Brickman, Daniel: 1 article (01/2020)
2.	Fong, Abraham: 1 article (01/2020)
3.	Johnson, Melissa: 1 article (01/2020)
4.	Lazarov, Mirella: 1 article (01/2020)
5.	Morgensztern, Daniel: 1 article (01/2020)
6.	Rossi, Michael: 1 article (01/2020)
7.	Rudin, Charles M: 1 article (01/2020)
8.	Cheng, Yun: 1 article (02/2011)
9.	Chi, Shu-ping: 1 article (02/2011)
10.	Gao, Rong: 1 article (02/2011)

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2020 - "SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study." 01/01/2020 - "This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. "
2.	Carcinoma (Carcinomatosis) 01/01/2020 - "SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study." 01/01/2020 - "This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. "
3.	Infections 05/01/2001 - "The in vivo antibacterial activity of SC-004, a pivaloyloxymethyl ester of SC-002, was 1.2-8 times more protective against systemic infections due to Streptococcus pneumoniae, Escherichia coli and Klebsiella pneumoniae than that of CFDN. "
4.	Neoplasms (Cancer) 02/01/2011 - "To study the anti-tumor mechanisms of ascidiacea analog SC002. " 02/01/2011 - "Primary study and anti-tumor mechanisms of analog from SC002." 02/01/2011 - "Ascidiacea analog SC002 can obviously induce the expression of P53, while decreasing the expression of Bcl-2 and VEGF, but have on effect on p21 in tumor tissue; ELISA shown that SC002 can also reduce the concentration of serum VEGF in tumor bearing mice, but did not affected the activity of Caspase-3, 8 and 9. SC002 have the anti-tumor function through promoting the expression of tumor suppressor gene p53, supress the expression of Bcl-2 and VEGF. " 02/01/2011 - "After treated the tumor cells with ascidiacea analog SC002, the changes of a serials of tumor associated cell signal molecules, including VEGF (vascular endothelial growth factor), P53, P21 and Bcl-2 et al, were detected by Western blot; further more the expression of serum VEGF in tumor-bearing mice and the activity of Caspase-3, 8, 9 in tumor tissue were investigated by ELISA; at last. "

Related Drugs and Biologics

1.	Immunoconjugates (Immunoconjugate)
2.	Ligands
3.	Esters
4.	SC004
5.	Caspase 3 (Caspase-3)
6.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)